Charles Schwab Investment Management Inc. Purchases 19,401 Shares of Disc Medicine, Inc. (NASDAQ:IRON)

Charles Schwab Investment Management Inc. increased its position in shares of Disc Medicine, Inc. (NASDAQ:IRON - Free Report) by 13.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 160,554 shares of the company's stock after purchasing an additional 19,401 shares during the period. Charles Schwab Investment Management Inc. owned 0.54% of Disc Medicine worth $7,890,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Amalgamated Bank raised its holdings in Disc Medicine by 76.9% during the second quarter. Amalgamated Bank now owns 568 shares of the company's stock valued at $26,000 after acquiring an additional 247 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Disc Medicine by 45.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company's stock worth $54,000 after purchasing an additional 337 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Disc Medicine in the 2nd quarter worth approximately $129,000. Quest Partners LLC purchased a new stake in Disc Medicine during the 3rd quarter valued at approximately $131,000. Finally, SG Americas Securities LLC raised its position in shares of Disc Medicine by 44.2% during the second quarter. SG Americas Securities LLC now owns 4,071 shares of the company's stock valued at $183,000 after buying an additional 1,247 shares during the last quarter. 83.70% of the stock is currently owned by institutional investors.

Disc Medicine Trading Down 2.3 %

Shares of NASDAQ IRON traded down $1.54 during trading hours on Wednesday, hitting $65.93. 412,756 shares of the company traded hands, compared to its average volume of 348,176. The stock has a market capitalization of $1.96 billion, a price-to-earnings ratio of -16.95 and a beta of 0.75. The company's 50 day moving average price is $56.26 and its 200 day moving average price is $49.06. Disc Medicine, Inc. has a 12 month low of $25.60 and a 12 month high of $77.60.

Disc Medicine (NASDAQ:IRON - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.89) earnings per share for the quarter, beating analysts' consensus estimates of ($1.04) by $0.15. Equities analysts anticipate that Disc Medicine, Inc. will post -4.05 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on IRON shares. Morgan Stanley raised shares of Disc Medicine from an "equal weight" rating to an "overweight" rating and set a $85.00 target price for the company in a research note on Tuesday, November 5th. HC Wainwright restated a "buy" rating and set a $118.00 price objective on shares of Disc Medicine in a research report on Monday. Wedbush reiterated an "outperform" rating and issued a $83.00 target price on shares of Disc Medicine in a research report on Monday. Cantor Fitzgerald restated an "overweight" rating and set a $85.00 price target on shares of Disc Medicine in a report on Tuesday, October 15th. Finally, Jefferies Financial Group started coverage on Disc Medicine in a research note on Wednesday, October 23rd. They issued a "buy" rating and a $89.00 price objective on the stock. Nine analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $87.50.

Insider Activity at Disc Medicine

In other Disc Medicine news, insider William Jacob Savage sold 9,158 shares of the company's stock in a transaction on Friday, November 15th. The stock was sold at an average price of $59.64, for a total value of $546,183.12. Following the transaction, the insider now owns 40,405 shares of the company's stock, valued at $2,409,754.20. This represents a 18.48 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director William Richard White sold 7,136 shares of the company's stock in a transaction dated Monday, November 4th. The stock was sold at an average price of $58.61, for a total transaction of $418,240.96. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 32,836 shares of company stock worth $2,038,816. Insiders own 4.24% of the company's stock.

Disc Medicine Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.